In Phase 1 clinical testing, intratumoral OX40L monotherapy in 39 patients exhibited a favourable safety profile (no dose-limiting toxicities), with 6/14 evaluable patients achieving stable disease for 14 weeks and 4 demonstrating tumor shrinkage both at injected and distant sites, accompanied by increased intratumoral OX40L expression and pro-inflammatory gene signatures [205]. The gene discussed is TNFSF4; the disease is neoplasm.